Flagship Merges 3 Startups to Turn Cause and Effect Insights Into Novel Medicines

Flagship Pioneering unveiled Etcelera, a brand new startup fashioned by combining three of the agency’s portfolio corporations. Etcelera’s method to drug R&D focuses on “causal intelligence,” which Flagship defines as predicting and understanding trigger and impact in biology.

The submit Flagship Merges 3 Startups to Flip Trigger and Impact Insights Into Novel Medicines appeared first on MedCity Information.

Source link